PTC Therapeutics, Inc. (PTCT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$60.59-3.89%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge PTC Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-11.8% · beyond scale

+10% or more+5%0%−5%−10% or less

2.68 → 2.37 EPS · FY ending Dec 31, 2027 · 8 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 7 to 8; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	319M
EPS	—	0.189
FY 2026 · Annual
Revenue	$850M–$950M	1.26B
EPS	—	1.175
FY 2027 · Annual
Revenue	—	1.38B
EPS	—	2.367

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Effective use of capital including share buybacks	A supporting condition in PTC Therapeutics, Inc.'s published investment case. The stated target is Maintain buyback program and manage debt prudently.	Under Pressure	Capital moves worsen financial health or dilute shareholders	Qualitative: 2 negative capital events (debt, equity sale) vs target of prudent management PTC announced acquisition of ST-920, beat Q2 estimates, but filed for new debt and unregistered equity sales. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Non-GAAP R&D and SG&A expenses within $680-$720 million in 2026	Costs are controlled within $680-$720 million.	Broken	Expenses exceed $720 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Non-GAAP R&D and SG&A expense guidance remained steady at $680-$720 million for 2026. Actual combined non-GAAP R&D and SG&A expenses were approximately $163.6 million in 2026-Q1 and $156.5 million in 2026-Q2, showing disciplined expense management. The trajectory is delivering within guided expense ranges. Delivery assessment Oct 24, 2026
Product revenue reaches $750-$850 million in 2026	Product sales rose from $153 million to $225 million.	Intact	Product revenue falls below $750 million in FY26	Product revenue: $238.819M FY2026-Q2; reported segment. Published target: $750-$850 million. Target period is not explicitly aligned with this observation. Source published Jul 30, 2026238,819,000 USD · source valueLast status assessment Oct 24, 2026 Measurement source Product · reported segment FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_segment_revenue. Reference: 2026-Q2. Source status: vendor observation. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Product revenue guidance was raised from $750-$850 million in 2026-Q1 to $850-$950 million in 2026-Q2. Reported product revenue increased from $226 million in 2026-Q1 to $239 million in 2026-Q2, supported by Sephience growth. The trajectory shows delivering growth consistent with raised guidance. Delivery assessment Oct 24, 2026
Total revenue reaches $1.08-$1.18 billion in 2026	A primary condition in PTC Therapeutics, Inc.'s published investment case. The stated target is $1.08-$1.18 billion.	Broken	Total revenue falls below $1.08 billion in FY26	Revenue: $360.519M FY2026-Q2; GAAP. Published target: $1.08-$1.18 billion. Target period is not explicitly aligned with this observation. Source published Jul 30, 2026360,519,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 745851e3-5543-4297-9dc1-9b3560dc803e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management raised full-year 2026 total revenue guidance from $1.08-$1.18 billion in 2026-Q1 to $1.18-$1.28 billion in 2026-Q2, with product revenue guidance raised from $750-$850 million to $850-$950 million. Reported total revenue grew from $272.6 million in 2026-Q1 to $360.5 million in 2026-Q2. The trajectory is delivering consistent revenue growth and upward guidance revisions. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$2.37

Unavailable → $2.37 · observed estimates

FY2027 revenue$1.38B

$1.35B → $1.38B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$1,345,239,220	3 / 13
2026-07-25	Unavailable	$1,343,729,940	3 / 13
2026-07-26	Unavailable	$1,343,729,940	3 / 13
2026-07-27	Unavailable	$1,343,729,940	3 / 13
2026-07-28	Unavailable	$1,343,729,940	3 / 13
2026-07-29	Unavailable	$1,343,729,940	3 / 13
2026-07-30	$2.58	$1,343,710,221	7 / 10
2026-07-31	$2.58	$1,343,710,221	7 / 10
2026-08-01	$2.58	$1,343,710,221	7 / 10
2026-08-02	Unavailable	$1,351,285,490	3 / 13
2026-08-03	$2.77	$1,359,111,928	7 / 10
2026-08-04	$2.77	$1,359,111,928	7 / 10
2026-08-05	$2.77	$1,359,111,928	7 / 10
2026-08-06	$2.77	$1,359,111,928	7 / 10
2026-08-07	$2.77	$1,359,111,928	7 / 10
2026-08-08	Unavailable	$1,361,778,060	3 / 13
2026-08-09	Unavailable	$1,361,778,060	3 / 13
2026-08-10	$2.77	$1,359,111,928	7 / 10
2026-08-12	$2.77	$1,359,111,928	7 / 10
2026-08-13	$2.77	$1,359,111,928	7 / 10
2026-08-14	$2.77	$1,359,111,928	7 / 10
2026-08-15	$2.77	$1,359,111,928	7 / 10
2026-08-16	$2.77	$1,359,111,928	7 / 10
2026-08-17	$2.77	$1,359,111,928	7 / 10
2026-08-18	$2.77	$1,359,111,928	7 / 10
2026-08-19	$2.77	$1,359,111,928	7 / 10
2026-08-20	$2.68	$1,369,318,121	7 / 10
2026-08-21	$2.68	$1,369,318,121	7 / 9
2026-08-22	$2.68	$1,369,318,121	7 / 9
2026-08-23	$2.68	$1,369,318,121	7 / 9
2026-08-24	$2.68	$1,369,318,121	7 / 9
2026-08-25	$2.68	$1,369,318,121	7 / 9
2026-08-26	$2.68	$1,369,318,121	7 / 9
2026-08-27	$2.68	$1,369,318,121	7 / 9
2026-08-28	$2.68	$1,369,318,121	7 / 9
2026-08-29	$2.68	$1,369,318,121	7 / 9
2026-08-30	$2.68	$1,369,318,121	7 / 9
2026-08-31	$2.68	$1,369,318,121	7 / 9
2026-09-01	$2.68	$1,369,318,121	7 / 9
2026-09-02	$2.68	$1,369,318,121	7 / 9
2026-09-03	$2.68	$1,369,307,351	7 / 9
2026-09-04	$2.68	$1,369,307,351	7 / 9
2026-09-05	$2.68	$1,369,307,351	7 / 9
2026-09-06	$2.68	$1,369,307,351	7 / 9
2026-09-07	$2.68	$1,369,307,351	7 / 9
2026-09-08	$2.68	$1,369,307,351	7 / 9
2026-09-09	$2.68	$1,369,307,351	7 / 9
2026-09-10	$2.68	$1,369,307,351	7 / 9
2026-09-11	$2.68	$1,369,307,351	7 / 9
2026-09-12	$2.68	$1,369,625,813	7 / 9
2026-09-13	$2.68	$1,369,625,813	7 / 9
2026-09-14	$2.68	$1,369,625,813	7 / 9
2026-09-15	$2.71	$1,376,048,890	7 / 9
2026-09-16	$2.71	$1,376,048,890	7 / 9
2026-09-17	$2.71	$1,376,048,890	7 / 9
2026-09-18	$2.71	$1,376,048,890	7 / 9
2026-09-19	$2.71	$1,376,048,890	7 / 9
2026-09-20	$2.71	$1,376,048,890	7 / 9
2026-09-21	$2.71	$1,376,048,890	7 / 9
2026-09-22	$2.71	$1,376,048,890	7 / 9
2026-09-23	$2.68	$1,376,918,121	7 / 9
2026-09-24	$2.68	$1,376,918,121	7 / 9
2026-09-25	$2.68	$1,376,918,121	7 / 9
2026-09-26	$2.68	$1,376,918,121	7 / 9
2026-09-27	$2.68	$1,376,918,121	7 / 9
2026-09-28	$2.68	$1,376,918,121	7 / 9
2026-09-29	$2.68	$1,376,918,121	7 / 9
2026-09-30	$2.68	$1,376,918,121	7 / 9
2026-10-01	$2.68	$1,376,918,121	7 / 9
2026-10-02	$2.68	$1,376,918,121	7 / 9
2026-10-03	$2.68	$1,376,918,121	7 / 9
2026-10-04	$2.68	$1,376,918,121	7 / 9
2026-10-05	$2.68	$1,376,918,121	7 / 9
2026-10-06	$2.68	$1,376,918,121	7 / 9
2026-10-07	$2.68	$1,376,918,121	7 / 9
2026-10-08	$2.55	$1,376,918,121	7 / 9
2026-10-09	$2.55	$1,376,916,505	7 / 9
2026-10-10	$2.48	$1,371,514,813	7 / 9
2026-10-11	$2.48	$1,371,514,813	7 / 9
2026-10-12	$2.48	$1,371,514,813	7 / 9
2026-10-13	$2.48	$1,371,514,813	7 / 9
2026-10-14	$2.48	$1,371,514,813	7 / 9
2026-10-15	$2.48	$1,371,514,813	7 / 9
2026-10-16	$2.46	$1,374,365,370	7 / 10
2026-10-17	$2.46	$1,374,365,370	7 / 10
2026-10-18	$2.37	$1,377,138,347	8 / 11
2026-10-19	$2.37	$1,377,138,347	8 / 11
2026-10-20	$2.37	$1,377,147,679	8 / 11
2026-10-21	$2.37	$1,377,147,679	8 / 11
2026-10-22	$2.37	$1,377,147,679	8 / 11
2026-10-23	$2.37	$1,377,147,679	8 / 11
2026-10-24	$2.37	$1,377,147,679	8 / 11

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	10	5	1
2026-06-01	11	3	1
2026-07-01	11	2	1
2026-08-01	11	2	1
2026-09-01	12	2	1
2026-10-01	13	2	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 13 Buy / Strong Buy · 2 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Raymond JamesOct 20

$106.00New observation · no comparable prior

UBSOct 15

$90.00New observation · no comparable prior

RBC CapitalOct 8 · prior Jul 7

$85.00 → $75.00-11.8%

$0$58.30$116.60

0 raises · 1 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Effective use of capital including share buybacksPublished status: Under Pressure
Non-GAAP R&D and SG&A expenses within $680-$720 million in 2026Published status: Broken
Product revenue reaches $750-$850 million in 2026Product revenue: $238.819M
Total revenue reaches $1.08-$1.18 billion in 2026Published status: Broken

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.3%Typical daily move · historical

Downside history

-33.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

PTC Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-oriented healthcare business, with recent financial performance strong and management’s revenue priorities on track. The long-term thesis is intact, but earnings quality and management execution are rated neutral, and confidence in the overall evidence is medium.

What's priced into PTC Therapeutics, Inc.

PTCT is valued at a sizable premium to peers, and the valuation model labels that premium as durable. Pricing is tagged as justified, with low fragility, but the estimated expectations gap is negative; model confidence in that estimate is low.

What the fundamentals likely do

Near-term, revenue momentum is supported by higher 2026 guidance and growth in product revenue, while reported expenses remain within management’s range. A guidance cut on the next call is a key risk, and recent earnings surprises have been erratic despite a quiet near-term risk rating.

What PTC Therapeutics, Inc. hinges on

The multi-year view hinges on continued revenue growth and management delivering against raised product and total revenue guidance while managing expenses. Near-term, a guidance cut or worsening employment data could pressure the business outlook, while continued strength from major healthcare peers could support sector momentum.